 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral TherapyU.S. Centers for Disease Control and Prevention • Medical News
December 5, 2006
On Friday, Pfizer Inc. announced plans to allow HIV/AIDS patients expanded access to a drug not yet approved by regulators but in late-stage clinical trials. Maraviroc belongs to the CCR5 antagonists class of drugs; these work by trying to block HIV from gaining entrance to white blood cells, rather than by fighting the virus inside the cells. The new program will allow patients resistant to other treatments to begin accessing the new drug. In the next few months, Pfizer will start enrolling patients from more than 30 countries in the program, in which they will receive the new drug along with background therapy. Researchers will monitor their progress.
Back to other news for December 5, 2006
Search the Newsroom archive
Excerpted from:
Associated Press
12.01.2006
This article was provided by U.S. Centers for Disease Control and Prevention, and is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
  |
  |